Blog

Why CQAs Matter More for LNPs Than for Conventional Drug Products For a conventional small molecule tablet, the critical quality attributes that determine in vivo performance, dissolution rate, disintegration time, content uniformity, are relatively straightforward to measure and control. For a lipid nanoparticle (LNP) system, the relationship between physicochemical properties and in vivo behaviour is […]

The Complexity Behind the Acronym Antibody-drug conjugates (ADCs) are a class of targeted oncology therapeutics that combine the selectivity of a monoclonal antibody with the potency of a cytotoxic small molecule payload. The concept is elegant: deliver a chemotherapy agent directly to the tumour cell, spare normal tissue, and improve the therapeutic index over conventional […]

The Site Built for Difficult Molecules Not every pharmaceutical development programme involves a straightforward API in a standard formulation. Some molecules are highly cytotoxic. Some are scheduled narcotics. Some are biologically active at doses measured in micrograms. These are not unusual compounds at the edges of drug development. They are increasingly common in oncology, neurology, […]

Where the Clinical Trial Meets the Laboratory Ardena’s Assen facility sits at the intersection of two things that are normally separated: the bioanalytical laboratory that measures what is happening in patients and the clinical supply operation that gets the drug to them. Bringing these capabilities together under one roof is not just operationally convenient. It […]

A Site Built Around Nanoparticles Ardena’s facility in Oss, the Netherlands, is not a general pharmaceutical site that also does nanomedicines. It is a site designed from the ground up for nanoparticle development and manufacturing. The equipment, the analytical infrastructure, the technical expertise, and the quality systems are all configured around the specific demands of […]

Same Data, Two Submissions If your clinical programme runs trials in both the European Union and the United States, you will submit essentially the same scientific data to two different regulatory agencies in two different formats with two different sets of expectations. The Investigational Medicinal Product Dossier (IMPD) goes to the relevant national competent authority […]

The Site That Does the Most Of all Ardena’s European sites, Ghent carries the broadest scope. It is where solid state research happens. It is where oral solid development and manufacturing runs. It is also where sterile injectables, lyophilised products, and complex parenteral formulations are developed and manufactured under GMP. For a programme that spans […]

Beyond the Batch Paradigm Pharmaceutical tablet manufacturing has been batch-based for most of its history. Raw materials in, process step by step, finished product out, test and release. The batch is a defined, auditable unit of production with a clear beginning and end. Continuous manufacturing challenges that model. Materials flow through an integrated process train […]

The Problem with Testing at the End Traditional pharmaceutical manufacturing is built around the idea of testing finished product. You make a batch, you sample it, you test it, and you decide whether it passes. The problem is that by the time you know a batch is out of specification, you have already used the […]

The Double Problem The molecules that generate the most clinical excitement are often the ones that cause the most formulation headaches. Modern oncology APIs, for example, tend to be both highly potent (small doses, strict containment requirements) and poorly soluble (BCS Class II or IV, significant bioavailability challenges). Solving one problem in isolation is hard […]

The Question Nobody Asks Early Enough When you are developing a nanoparticle drug product, the bioanalytical question you need to answer is not simply ‘how much drug is in the blood?’ It is ‘which form of the drug are you measuring, and what does that tell you about what is actually happening in the patient?’ […]

A Different Kind of Drug CAR-T cell therapies are not small molecules. They are not even biologics in the conventional sense. They are living, replicating therapeutic agents: a patient’s own T cells, extracted, genetically modified to express a chimeric antigen receptor, expanded ex vivo, and reinfused to hunt and destroy tumour cells. That extraordinary mechanism […]